Format

Send to

Choose Destination
Clin Infect Dis. 2003 Jun 15;36(12):1585-92. Epub 2003 Jun 5.

A review of low-dose ritonavir in protease inhibitor combination therapy.

Author information

1
Division of Infectious Diseases, The Ottawa Hospital-General Campus, Ottawa, ON, Canada K1H 8L6. ccooper@ottawahospital.on.ca

Abstract

The pharmacokinetics of protease inhibitors center around the microsomal enzyme cytochrome P-450 3A4. As a potent inhibitor of this enzyme, ritonavir can increase the bioavailability and half-life of coadministered protease inhibitors. Evidence suggests that increased exposure to protease inhibitors is clinically relevant. Antiretroviral treatment with low-dose ritonavir-boosted lopinavir, indinavir, and saquinavir has durable virological activity and shows impressive immune reconstitution. Although tolerable in most cases, gastrointestinal side effects, hepatotoxicity, and blood lipid abnormalities remain relevant issues. Additional study will elucidate the advantages and disadvantages of twice-daily, low-dose ritonavir-boosted regimens and determine whether once-daily regimens based on this principle will have a lasting role in clinical practice.

PMID:
12802760
DOI:
10.1086/375233
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center